Nilzio A Da Silva

Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

Mark C. Genovese, James D. McKay, Eduardo Mysler et al. · Arthritis & Rheumatism · 2008 · 858 citations

Medicine, Pharmacology, Pharmacotherapy +16

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)

Bernardo A. Pons‐Estel, Eloísa Bonfá, Enrique R. Soriano et al. · Annals of the Rheumatic Diseases · 2018 · 151 citations · Full text

Life Sciences, Immunology, Internal Medicine +10

Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort

Luis Alonso González, Octavio Martínez Betancur, Graciela S. Alarcón et al. · Seminars in Arthritis and Rheumatism · 2015 · 64 citations

Life Sciences, Hematology, Immunology +16

Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort

Manuel F. Ugarte‐Gil, Daniel Wojdyla, Guillermo Pons‐Estel et al. · The Journal of Rheumatology · 2019 · 36 citations

Medicine, Immunology, Clinical Pharmacology +13

Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)

Cristina Reátegui-Sokolova, Manuel F. Ugarte‐Gil, Guillermina Harvey et al. · RMD Open · 2020 · 34 citations · Full text

Medicine, Nephrology, Pathology +17